Bronchopneumonia

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 1, 2022
Government, ABSSSI, BARDA, NASDAQ, Development, Office of Inspector General, U.S. Department of Health and Human Services, Twitter, Anthrax, LLC, Bronchopneumonia, Biomedical Advanced Research and Development Authority, Employment, Acne, Public health, Company, GLOBE, NTM, U.S. Department of Defense Strategy for Operating in Cyberspace, Degenerative disease, LinkedIn, Nasdaq, Pharmaceutical industry, Vaccine

The stock options are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement covering each grant.

Key Points: 
  • The stock options are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement covering each grant.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

Retrieved on: 
Tuesday, January 18, 2022
Telephone, Urinary tract infection, Private Securities Litigation Reform Act, SEC, Tablet, NASDAQ, Proxy, GLOBE, Merck, U.S. Securities and Exchange Commission, Bronchopneumonia, Infection, Therapy, Fosfomycin, Company, Food and Drug Administration, Food, Internet, Proxy statement, Death Cab for Cutie, EGM, Security (finance), Pyelonephritis, Animal

DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021 (Proxy Statement). The EGM will reconvene on Thursday, March 24, 2022, beginning at 5:00 p.m. Irish time (12:00 p.m., U.S. Eastern Time) at 25-28 North Wall Quay, Dublin 1, Ireland.

Key Points: 
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

Retrieved on: 
Friday, January 14, 2022
Telephone, Urinary tract infection, Private Securities Litigation Reform Act, SEC, Tablet, NASDAQ, Proxy, GLOBE, Merck, U.S. Securities and Exchange Commission, Bronchopneumonia, Infection, Therapy, Fosfomycin, Company, Method, Food and Drug Administration, Food, Internet, Proxy statement, Death Cab for Cutie, EGM, Security (finance), Pyelonephritis, Animal

DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 14, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021 (Proxy Statement). The EGM will reconvene on Tuesday, January 18, 2022, beginning at 7:00 p.m. Irish time (2:00 p.m., U.S. Eastern Time) at 25-28 North Wall Quay, Dublin 1, Ireland.

Key Points: 
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, January 3, 2022
Twitter, Bronchopneumonia, BARDA, Office of Inspector General, U.S. Department of Health and Human Services, NTM, ABSSSI, LLC, U.S. Department of Defense Strategy for Operating in Cyberspace, Acne, GLOBE, Company, Degenerative disease, Development, NASDAQ, Anthrax, Employment, Nasdaq, Biomedical Advanced Research and Development Authority, LinkedIn, Government, Public health, Pharmaceutical industry, Vaccine

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021

Retrieved on: 
Wednesday, December 22, 2021
U.S. Securities and Exchange Commission, Merck, Urinary tract infection, Pyelonephritis, Internet, Telephone, Infection, NASDAQ, Bronchopneumonia, Proxy statement, Private Securities Litigation Reform Act, Method, Proxy, SEC, Food and Drug Administration, Cuties, Tablet, EGM, Company, Fosfomycin, Therapy, Security (finance), Food, GLOBE, Animal

Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Key Points: 
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Tuesday, December 21, 2021
Conference, Merck, Urinary tract infection, Pyelonephritis, Webcast, NASDAQ, Bronchopneumonia, Tuberculosis verrucosa cutis, Food and Drug Administration, Tablet, Company, Fosfomycin, Therapy, Food, GLOBE, Infection, Pharmaceutical industry

The presentation will be available on-demand beginning on Monday, January 10 at 7:00am ET.

Key Points: 
  • The presentation will be available on-demand beginning on Monday, January 10 at 7:00am ET.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 1, 2021
U.S. Department of Defense Strategy for Operating in Cyberspace, Government, NTM, Bronchopneumonia, Degenerative disease, Office of Inspector General, U.S. Department of Health and Human Services, Company, Biomedical Advanced Research and Development Authority, Acne, Anthrax, BARDA, Nasdaq, Twitter, ABSSSI, GLOBE, LLC, Development, Public health, LinkedIn, Employment, NASDAQ, Pharmaceutical industry, Vaccine

The stock options are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement award agreement covering each grant.

Key Points: 
  • The stock options are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement award agreement covering each grant.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

Retrieved on: 
Monday, November 29, 2021
Patient, CAP, Review, Bronchopneumonia, Merck, Private Securities Litigation Reform Act, Awareness, Sumitomo Group, CDE, SEC, Sumitomo Dainippon Pharma, COVID-19, Food and Drug Administration, Community-acquired pneumonia, GLOBE, Infection, Tablet, NDA, Cuties, Lefamulin, Fosfomycin, Therapy, Pyelonephritis, Growth, NASDAQ, Urinary tract infection, Food, Hercules, Pharmaceutical industry

This filing brings Nabriva and Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. one step closer to their goal of offering lefamulin to patients with CAP in China.

Key Points: 
  • This filing brings Nabriva and Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. one step closer to their goal of offering lefamulin to patients with CAP in China.
  • To date there have been 4 approvals and two applications pending review, said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack

Retrieved on: 
Thursday, November 11, 2021
CYP3A4, Therapy, Moxifloxacin, CDAD, Food, COVID-19, Legionella pneumophila, Infection, Staphylococcus aureus, Review, Insomnia, Risk, Cutis laxa, Hypersensitivity, Fosfomycin, Pregnancy, Chlamydia pneumoniae, Clostridioides, Food and Drug Administration, Haemophilus influenzae, Streptococcus pneumoniae, Complicated, Research, Woman, Vomiting, Headache, Pyelonephritis, GLOBE, Tablet, Marketing, Patient, FDA, Private Securities Litigation Reform Act, NASDAQ, Fetus, CYP3A, Human, Mycoplasma pneumoniae, Liver, U.S. Securities and Exchange Commission, Arrhythmia, Nausea, Pharmacy, QT, Urinary tract infection, ABSSSI, Merck, European Union, Linezolid, Diarrhea, IV, Birth, Bacteria, Bronchopneumonia, Physician, Hypokalemia, Pharmaceutical industry, Vaccine, Birth control

XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP).

Key Points: 
  • XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP).
  • Our community-based sales force is excited to communicate the availability of the 10-count oral pack or X pack to their target customers.
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.
  • Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP.

Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021
Public health, Government, ABSSSI, Security (finance), EST, Acne, Office of Inspector General, U.S. Department of Health and Human Services, Risk, BARDA, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Degenerative disease, LLC, NTM, Conference, U.S. Securities and Exchange Commission, GLOBE, Development, Biomedical Advanced Research and Development Authority, Bronchopneumonia, Webcast, Anthrax, Nasdaq, Pharmaceutical industry, Vaccine

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference.

Key Points: 
  • BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference.
  • A replay of the webcast can be accessed for up to 30 days following the live presentation.
  • Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remainingglobal rights.